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Evolution of nephrotic-associated focal segmental glomeru-
losclerosis and relation to the glomerular tip lesion.
Background. Several entities or variants within focal segmen-
tal glomerulosclerosis (FSGS) have been described, but their
changes with time and interrelationships are undetermined.
Methods. Changes with time were studied in two series of
segmental sclerosing lesions in the nephrotic syndrome, one
of 22 specimens from ten patients in a trial, the other of 176
specimens from 121 consecutive patients.
Results. The earliest lesions were probably all at the tubular
origin, equivalent to the tip variant of FSGS. In some patients,
lesions remained at this site, but progression to renal failure
was accompanied by morphologic progression, with develop-
ment of lesions at various sites, equivalent to FSGS, not other-
wise specified (NOS). Progression was more likely if there were
large lesions, abnormal mesangium, and extensive acute tubular
damage. Patients with lesions at the tubular origin at presenta-
tion had a shorter duration of symptoms and less chronic re-
nal damage than those with multiple lesions, were more likely
to have a complete response of the nephrotic syndrome, and
were less likely to progress to renal failure. Recurrent nephrotic
syndrome occurred in 12 of 14 allografts at risk, and was usu-
ally accompanied by lesions at the tubular origin, then multiple
lesions.
Conclusion. At least some patients with FSGS (NOS) have
evolved from the tip variant. The tip variant has been consid-
ered a distinct entity. Another interpretation is that it includes
two conditions, one an early form of classic FSGS, and the other
closely related to minimal change nephropathy (MCN), equiv-
alent to the glomerular tip lesion as originally defined.
The term focal segmental glomerulosclerosis (FSGS)
has been applied to segmental sclerosing lesions in dif-
ferent circumstances, such as in the nephrotic syndrome,
nonnephrotic proteinuria, states of reduced renal mass,
1See Editorial by Haas, p. 1188.
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and various glomerular disorders. There is recognition
that several morphologic entities have been included in
FSGS [1]. Whether these are variants of a single condition
has not been determined, nor has the relation between
them. In particular, there has been little work on their
changes with time.
The hypothesis of this study was that there were
changes with time in segmental sclerosing lesions in the
nephrotic syndrome. Our investigation was of two series
of patients who had more than one specimen. The first
series comprised patients with repeat specimens in the
United Kingdom Medical Research Council (MRC) 1960
trial of steroids in the nephrotic syndrome [2]. Advan-
tages of this series were that renal biopsies were collected
without reference to the original diagnosis, patients who
had a relapse usually had a repeat biopsy, and among
later specimens were autopsy kidneys, which were vir-
tually unobtainable afterwards. The second series com-
prised patients selected from all those with the nephrotic
syndrome seen at one nephrology unit in 18 years, and
had advantages that it was larger and more recent. Nei-
ther series included children under 13 years old.
METHODS
Repeat specimens in the MRC trial
In this trial, there were renal biopsies from 125 pa-
tients aged at least 15 years, with edema, at least 5 g pro-
teinuria per 24 hours, and serum albumin concentration
under 30 g/L [2]. Of 26 who had repeat specimens avail-
able for study [3], 16 were excluded with membranous
nephropathy (N = 8), minimal change nephropathy
(MCN) (N = 5), subendothelial membranoproliferative
glomerulonephritis (MPGN) (N = 2), and severe late
damage (N = 1). The ten patients studied had two re-
nal biopsies (N = 4), a biopsy and an autopsy (N =
4), three biopsies (N = 1), and two biopsies and an au-
topsy (N = 1). One slide, usually with one section, was
restained with periodic acid-methenamine silver (PA-
silver), and examined for these features [4, 5]: number
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of glomeruli, number of glomeruli with identifiable tubu-
lar origin, number of globally sclerosed glomeruli, and
whether mesangium appeared normal; appearance and
size of segmental lesions, their position related to tubular
origin and hilum, and number of glomeruli affected; and
marked acute tubular damage, detected mainly as flat-
tened epithelium, affecting at least a fourth of proximal
tubules. Mesangium was considered normal if the amount
of matrix and number of cells were not increased in com-
parison with those in reference glomeruli, for instance,
in thin glomerular basement membrane disease. A large
lesion occupied at least one third of the tuft. Epithelial
changes in segmental lesions were defined as any changes
in visceral epithelial cells, including crowding, swelling,
vacuolation, and granulation. Any of the following fea-
tures were called multiple lesions: (1) at least one lesion
away from the tubular origin, such as at the hilum or
mid tuft, and/or (2) lesions extending from tubular origin
to hilum, and/or (3) lesions at various sites in glomeruli.
Sections of autopsy kidneys were examined for a differ-
ence between outer and inner cortex, by drawing a line to
split the cortex into two zones, counting glomeruli with
segmental or global sclerosis, and expressing these as per-
centages of all glomeruli. A difference between the zones
of at least 15% in either count was arbitrarily considered
significant. Glomerular area was measured by an approx-
imate method [6]. The index of chronic damage was cal-
culated to measure damage as a proportion of cortical
cross-sectional area [7]. Patterns of change in segmental
abnormalities were identified.
Repeat specimens in the later series
Cases were selected from middle of 1985, following
another study [8], to the end of 2003, from 730 consec-
utive patients aged at least 13 years with the nephrotic
syndrome (edema, serum albumin concentration under
30 g/L, and proteinuria, at least 3.5 g/24 hours, or ra-
tio of urinary albumin to creatinine concentrations of at
least 300 mg/mmol). Patients were excluded with mem-
branous nephropathy (N = 218), MCN (N = 122), dia-
betic glomerulopathy (N = 65), lupus nephritis (N = 59),
amyloid (N = 51), acute postinfective glomerulonephri-
tis (N = 25), MPGN (N = 25), IgA nephropathy/Henoch
Scho¨nlein nephritis (N = 24), light chain glomerulopathy
(N = 6), vasculitic glomerulonephritis (N = 4), collaps-
ing glomerulopathy (N = 3), eclamptic glomerulopathy
(N = 3), immunotactoid glomerulopathy (N = 3), and
cryoglobulinaemic glomerulonephritis (N = 1). This left
121 patients with at least one renal biopsy containing
at least one segmental lesion. On electron microscopy,
none had Alport syndrome or other identifiable inher-
ited disorder. Of these 121 patients, 30 had more than
one specimen, including specimens of renal allografts.
Twenty-one had two biopsies, two had three, and seven
had various biopsies (N = 13), nephrectomies (N = 3),
allograft biopsies (N = 15), and allograft nephrectomies
(N = 6). No autopsies were available. On every biopsy,
there were at least six slides, with about six serial sec-
tions per slide. Sections were examined as in the MRC
series. Nephrectomy kidneys were studied in the same
way as MRC autopsy kidneys. Clinical features included
treatment with immunosuppressive drugs (steroids, aza-
thioprine, cyclosporine, cyclophosphamide, or mycophe-
nolate mofetil), development of end-stage renal failure
(ESRF), and nephrotic recurrence after transplantation.
Response of proteinuria was incomplete, if persistently
abnormal, or complete, if normal, either total below
0.2 g/24 hours or albumin/creatinine ratio below 3.0 mg/
mmol. Renal status at follow-up was defined as well (nor-
mal function, and no proteinuria, as defined for com-
plete response), or proteinuria, including the nephrotic
syndrome (with normal function), or renal impairment
(serum creatinine over 130 lmol/L, irrespective of pro-
teinuria). Other outcomes were ESRF (onset of per-
manent dialysis), and death before dialysis, with either
normal function or renal impairment. Outcomes were
mutually exclusive.
Statistical methods
Wilcoxon’s rank sum test was used to assess differences
in the MRC series in glomerular area, index of chronic
damage, and proportions of glomeruli with global scle-
rosis and segmental lesions. The t test was used to assess
these factors in the later series, and also age, duration of
symptoms, serum creatinine concentration, and length of
follow-up. Survival rates to the earlier of ESRF or death,
and to ESRF alone, were studied by the Kaplan-Meier
method and log rank test, and by the life-table method.
Spearman’s coefficient was used to assess correlations be-
tween outcome and various factors. The Cox proportional
hazards model was used to study the effect of different
patterns of lesions on outcome, after controlling for these
factors: index of chronic damage, proportion of glomeruli
with global sclerosis, and proportion with global sclero-
sis and segmental lesions. The conventional value of P <
0.05 was considered significant.
RESULTS
Repeat specimens in the MRC trial
Patients fell into two groups, differentiated by find-
ings in the last specimen (Table 1). MRC1 to MRC5
formed one group. These had segmental lesions in the
first biopsy that were all at the tubular origin when their
position could be determined, with foamy intracapillary
cells or hyaline material or mixtures, and adhesion be-
tween basement membranes of capillary loops and Bow-
man’s capsule (Fig. 1A to C). Epithelial changes were
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sometimes seen (Fig. 1B). Later specimens were at a me-
dian of 2 years after the first. These retained the adhe-
sion, sometimes just a thin band, often with hyalinosis
and sclerosis, and with little change in the position of
lesions, proportion of globally sclerosed glomeruli, and
index of chronic damage (Fig. 1D to F). In the autopsy
kidney (MRC3), there was little difference between inner
and outer cortex.
MRC6 to MRC10 formed the other group. In their first
biopsy, they had either lesions all at the tubular origin
when their position could be determined, or no lesions
(Fig. 2A to C). The last specimens were at a median of
1 year after the first and showed multiple lesions. There
was variability in number, size, and appearance of lesions,
with a higher index of chronic damage, and more globally
sclerosed glomeruli (Fig. 2D to F). Appreciable differ-
ences between outer and inner cortex were noted in two
of four autopsy kidneys. In MRC8 and MRC9, there were
more segmental lesions in the inner cortex, and these
were larger than in the outer cortex.
None of MRC1 to MRC5 was on dialysis at the time
of the last specimen, although at least four of MRC6
to MRC10 were. On clinical and morphologic grounds,
MRC1 to MRC5 were nonprogressive while MRC6 to
MRC10 were progressive. In initial biopsies, there were
no significant differences between these groups in propor-
tion of globally sclerosed glomeruli, glomerular area, or
index of chronic damage. The progressive group had large
lesions initially in three cases, and in the second biopsy in
MRC7. The progressive group also had a higher propor-
tion of glomeruli with lesions (means 32% vs. 17%) (P <
0.05). The only initial biopsy to have normal mesangium,
MRC1, was in the nonprogressive group, and two oth-
ers in this group had normal mesangium later. Extensive
acute tubular damage was seen in one nonprogressive
case and four progressive, and so were epithelial changes.
Repeat specimens in the later series (30 patients)
These 30 patients were divided on the basis of find-
ings in their initial specimen into 15 with segmental le-
sions all at the tubular origin, ten with multiple lesions,
and five with no segmental lesions (Table 2). There were
nonsignificant differences between patients with lesions
at the tubular origin, and those with multiple lesions,
in age at the time of the first specimen (means 30.7 vs.
37.9 years), duration of symptoms (0.2 vs. 2.0 years),
serum creatinine concentration (107 vs. 204 lmol/L),
glomerular area (28641 vs. 24246 lm2), and proportion
of glomeruli with segmental lesions (24.1% vs. 43.8%).
Those with lesions at the tubular origin had a significantly
smaller index of chronic damage (2.0% vs. 28.1%) (P <
0.03), and a significantly smaller proportion of globally
sclerosed glomeruli (0.6% vs. 23.3%) (P < 0.02).
Of the 15 with lesions at the tubular origin, two (cases
1 and 4) had only lesions at the tubular origin in their
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A B C
FED
Fig. 1. Findings in three patients in the Med-
ical Research Council (MRC) series who did
not progress. (A) MRC1, first biopsy. There is
a segmental lesion at the tubular origin. (B)
MRC2, first biopsy. A lesion at the tubular
origin has foamy intracapillary cells. Visceral
epithelial cells (arrows) are crowded on the
surface and vacuolated. (C) MRC3, biopsy.
There is an adhesion between tuft and Bow-
man’s capsule at the tubular origin (arrow).
(D) MRC1, second biopsy, 2 years later. There
is a thin adhesion (arrow) at the tubular ori-
gin. (E) MRC2, second biopsy, 3 years later.
There is a hyaline lesion at the tubular origin.
(F) MRC3, autopsy, 3 months later. There is
a sclerosed lesion at the tubular origin.
A B C
FE
D
Fig. 2. Findings in three patients in the Med-
ical Research Council (MRC) series who pro-
gressed. (A) MRC6, biopsy. There is no seg-
mental lesion but mesangium appears mildly
increased. (B) MRC9, biopsy. Four glomeruli
(arrows) have lesions at the tubular origin.
There is extensive acute tubular damage and
mild tubular atrophy. (C) MRC10, first biopsy.
There is a large lesion at the tubular origin.
(D) MRC6, autopsy, 2 years later. There are
multiple segmental lesions. (E) MRC9, au-
topsy, 1 year later. Glomeruli have multiple
lesions. There is tubular atrophy. (F) MRC10,
second biopsy, 6 months later. Glomeruli have
multiple lesions. There is marked tubular at-
rophy.
second biopsy, and these were thin adhesions (Fig. 3A and
B). Both had been treated with steroids and cyclosporine,
and were well, at 29 and 7 years, respectively, after the
first biopsy. The other 13 patients all progressed to have
multiple segmental lesions, seen in specimens at a me-
dian of 1.7 years after the first. Eleven were treated with
combinations of immunosuppressive drugs and two with
steroids alone. There were significant increases in the
index of chronic damage (2.3% to 47.6%) (P < 0.001)
and proportion of globally sclerosed glomeruli (0.7% to
28.0%) (P < 0.005), with a nonsignificant increase in the
proportion of glomeruli with segmental lesions (26.1%
to 41.5%) (Fig. 3C to F). The outcome was persistent
proteinuria in six, including three with the nephrotic
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Fig. 3. Findings in four patients in the later
series. (A) First biopsy. There is a lesion at
the tubular origin with epithelial changes (ar-
row). (B) Second biopsy in (A), 13 years later.
There is a thin adhesion at the tubular ori-
gin. (C) First biopsy. There is a large, foamy,
hyalinized and sclerosed lesion at the tubular
origin. (D) Second biopsy in (C), 11 months
later. Glomeruli have multiple lesions. (E)
First biopsy. Glomeruli have lesions at the
tubular origin (arrows). (F) Second biopsy in
(E), 7 years later. Glomeruli have lesions at
various positions, including at the tubular ori-
gin (arrow). (G) First biopsy. There is a lesion
away from both tubular origin and hilum, with
epithelial changes at the tubular origin (ar-
rows). (H) Second biopsy in (G), 2 months
later. There are multiple lesions. (I) Biopsy of
allograft in (G) at 2 months. There is a lesion
at the tubular origin.
syndrome, renal impairment in three, and ESRF in four.
ESRF was at a median of 5.6 years after the first biopsy.
In ten patients with multiple lesions, the lesions re-
mained multiple in later specimens, with a significant in-
crease in the proportion of globally sclerosed glomeruli
(23.3% to 58.1%) (P = 0.04) and a nonsignificant increase
in the index of chronic damage (28.1% to 52.6%). Five
were treated with steroids alone, three had combinations
of drugs, one had no immunosuppressive treatment, and
treatment was not known in the other one. Seven pa-
tients reached ESRF, at a median of 1.3 years after the
first specimen.
In five patients with no lesions at first, four were treated
with combinations of drugs, and one had steroids alone.
Four patients developed lesions at the tubular origin. One
of these (case 26) had only thin adhesions, resembling
Figures 1D and 3B, and was well at follow-up. Another
(case 30) progressed from lesions at the tubular origin
to multiple lesions. The fifth (case 27) developed multi-
ple lesions, and reached ESRF at 6.1 years after the first
biopsy.
Of 12 patients who reached ESRF, three subsequently
had nephrectomy for persistent nephrotic syndrome. In
two (cases 6 and 20), segmental and/or global glomeru-
lar changes were more marked or more advanced in the
inner cortex, and in one (case 27), changes were similar
between outer and inner cortex.
Recurrence in renal allografts
There were 15 renal transplants in 10 of 12 patients
with ESRF. One graft was lost immediately from ve-
nous thrombosis. Clinically evident nephrotic syndrome
recurred in 10 transplants, at a median of 5.5 months after
transplantation. Two grafts in one patient (case 6) had no
useful function, little or no urine output, and no clinically
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obvious recurrence, but had evidence of glomerular leak
of protein, with effacement of foot processes on electron
microscopy, IgG in tubular epithelial cells on immuno-
histologic study, and high concentration of protein in any
urine produced. Of these 12 grafts with proteinuria, nine
showed lesions at the tubular origin, with progression to
multiple in two (Fig. 3G to I). Three transplants had mul-
tiple lesions. In six allograft nephrectomies, segmental
and/or global glomerular changes were more marked or
more advanced in the inner cortex in two (cases 23 and
27, second graft), more marked in the outer cortex in one
(case 27, first graft), and approximately equal in three
(cases 6, first and third grafts, and 16, second graft).
Single biopsies in later series (91 patients)
In this group, lesions all at the tubular origin were seen
in 61 patients, four with only thin adhesions. In three of
the 61, treatment was not known. Four had no steroids
or other immunosuppressants. The other 54 were treated
with steroids alone (36) or steroids and other immuno-
suppressants (18), which were combinations of various
drugs in seven, cyclosporine in five, cyclophosphamide in
three, mycophenolate mofetil in two, and azathioprine in
one. Forty-four of 57 with follow-up had a complete re-
sponse, at a median of 4.5 months after biopsy, and 20 of
these had at least one relapse of the nephrotic syndrome.
Twenty-four of 57 with follow-up were well, at a median
of 6.9 years after biopsy, including three who had no im-
munosuppressive treatment. Eighteen had proteinuria,
at a median of 5.9 years. Nine had renal impairment, at a
median of 4 years, and another one developed ESRF at
12.6 years. Five died, at a median of 8.5 years, three with
normal function and two with renal impairment.
Of 30 patients with multiple lesions, treatment was
not known in six. Fourteen had no steroids or other im-
munosuppressants. Five others were treated with steroids
alone and five with steroids and other immunosuppres-
sants, which were combinations of various drugs in three,
and cyclosporine in two. Of 27 with follow-up, none had
complete resolution of the nephrotic syndrome. Ten had
proteinuria alone, including two with the nephrotic syn-
drome, at a median of 4.3 years after biopsy. Ten had renal
impairment, at a median of 1.8 years. Another one died
at 5.5 years, with renal impairment. Six developed ESRF,
at a median of 1 year, and one of these had a transplant,
lost immediately from venous thrombosis.
The four patients with thin adhesions in their only
biopsy, and the three who had these after biopsies either
without lesions (case 26) or with lesions at the tubular ori-
gin (cases 1 and 4) were similar. All seven had a long his-
tory of relapsing, steroid-responsive nephrotic syndrome
before the biopsy that showed thin adhesions (median
duration 13.2 years), all had a complete response after
biopsy, and all were well at follow-up (median 1.4 years).
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Fig. 4. Survival from the first or only renal biopsy until end-stage renal
failure (ESRF) in 72 patients with lesions at the tubular origin (lower
line) and 36 patients with multiple lesions (upper line). Marks on lines
indicate patients censored at last follow-up, or who died before ESRF.
Log rank test v 2 = 22.8 (P < 0.001).
In the 91 patients with a single biopsy, there were
nonsignificant differences between those with lesions at
the tubular origin and those with multiple lesions in age
(means 50.6 vs. 49.8 years), serum creatinine concentra-
tion (152 vs. 212 lmol/L), and glomerular area (28343 vs.
31074 lm2). Those with lesions at the tubular origin had
significantly shorter duration of symptoms, when the four
with thin adhesions were excluded (0.4 vs. 3.5 years) (P <
0.02), significantly longer follow-up (6.2 vs. 3.7 years) (P <
0.03), significantly smaller index of chronic damage (4.7%
vs. 31.7%) (P < 0.001), significantly smaller proportion
of globally sclerosed glomeruli (4.5% vs. 32.9%) (P <
0.001), and significantly smaller proportion of glomeruli
with segmental lesions (16.9 vs. 27.4%) (P < 0.04).
Later series of 121 patients: Overall outcome
and risk markers
After omission from the 121 patients of seven without
follow-up, one whose first specimen was nephrectomy af-
ter ESRF (case 20), and five with no segmental lesions in
their first biopsy (cases 26 to 30), the other 108 were di-
vided into 72 with lesions at the tubular origin in their first
or only specimen, and 36 with multiple lesions in their first
or only specimen. When the end-point was ESRF or death
before ESRF, survival at 10 years after biopsy, computed
by the life-table method, was 84% in those with lesions at
the tubular origin, and 45% in those with multiple lesions
(log rank test v 2 = 17.9) (P < 0.001). This difference was
even more marked for ESRF alone, when survival was
94% and 53% respectively (log rank test v 2 = 22.8) (P <
0.001) (Fig. 4).
In the Cox model, after controlling for index of chronic
damage, proportion of glomeruli with global sclerosis,
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and proportion with global sclerosis and segmental le-
sions, the position of lesions, whether at the tubular ori-
gin or multiple, had no significant independent relation
to outcome, nor did any of the other variables.
None of the 36 patients with multiple lesions was well
at follow-up, at a median of 2 years after the first or only
biopsy. Twelve reached ESRF, at a median of 1.2 years.
Eleven had proteinuria, including two with the nephrotic
syndrome, at a median of 4.3 years. Twelve had renal
impairment, at a median of 2 years. One died with renal
impairment at 5.5 years.
In those with lesions at the tubular origin, risk markers
for any outcome other than well were analyzed in the
first specimen that showed these lesions, based on the
findings in the MRC series. There were 71 in this group,
67 with lesions at the tubular origin in their first or only
specimen and at least 6 months of follow-up, and four
who developed lesions at the tubular origin after a biopsy
with no lesions. Twenty-five were well at follow-up, at a
median of 7.3 years after the relevant biopsy. Forty-six
had any other outcome, at a median of 6.4 years. Twenty-
three had proteinuria, including three with the nephrotic
syndrome, at a median of 6.1 years. Thirteen had renal
impairment, at a median of 4.9 years. Five had ESRF, at
a median of 7.1 years. Five died, three with normal renal
function, and two with renal impairment, at a median of
8.5 years.
There were nonsignificant differences between those
who were well and the others in age at biopsy (means
40.0 vs. 49.8 years), serum creatinine concentration (141
vs. 153 lmol/L), glomerular area (27 377 vs. 28 759 lm2),
and proportion of globally sclerosed glomeruli (3.4% vs.
4.5%). Those who were well had a significantly smaller
index of chronic damage (1.8% vs. 5.7%) (P < 0.01), and
a significantly smaller proportion of glomeruli with seg-
mental lesions (12.2% vs. 21.3%) (P < 0.02). There was
a correlation between the proportion of glomeruli with
segmental lesions and the presence of large lesions (r =
0.43, P < 0.001). There was a correlation between any out-
come other than well, and the total number from 0 to 3 of
presence of three factors, namely, large segmental lesions,
mesangial increase, and extensive acute tubular damage
(r = 0.55, P < 0.001). That is, the more of these factors that
were present, the more likely was an outcome other than
well. Each of these factors individually had a weaker cor-
relation with outcome. The correlation was not strength-
ened by inclusion of presence of epithelial changes. These
had no significant correlation with outcome.
DISCUSSION
This study showed that there were changes with time in
segmental sclerosing lesions in the nephrotic syndrome.
These had not previously been investigated in such de-
tail, nor in so many patients with repeat specimens, nor
with such prolonged follow-up. This has helped to clarify
the relation between some of the entities in a proposed
classification of FSGS [1].
Changes with time in segmental sclerosing lesions
In the MRC series, the first lesions in most patients
were probably all at the tubular origin. The word “proba-
bly” is used for two reasons. One is that glomerular land-
marks were not present in every glomerulus and without
these the position of lesions could not be definitely deter-
mined, but in 36 (72%) of 50 glomeruli with lesions in first
biopsies in the MRC series, these were definitely at the
tubular origin. In the other glomeruli, the lesions were
not shown to be definitely anywhere else, and a position
at the tubular origin was not excluded. The second reason
to qualify the site of lesions is that the largest number of
glomeruli with lesions in any initial MRC biopsy was 20,
which is a tiny fraction of all glomeruli in a kidney. There
is always the problem that a biopsy may not be represen-
tative, and the distribution of lesions may be misleading.
There was more certainty about the position of lesions
in the later series because serial sections were available.
The consistency of the findings in this paper supports the
conclusions of another study that used many serial sec-
tions to show the relation of early lesions to the tubular
origin [9]. Not every lesion could be seen with the tubular
opening on the same section, and this explains why a le-
sion and the opening are shown in some illustrations (for
example, Figs. 1A and 2C), but not in others (for example,
Figs. 1C and 3A).
Patients in the MRC series who progressed to ESRF
showed development of lesions away from the tubular
origin, called multiple lesions for convenience. The pro-
gressive and nonprogressive groups were too small to be
sure whether any differences were due to treatment or
lack of it, although at least two in each group had pred-
nisone. Patients in the later series included four with no
lesions at first who developed lesions at the tubular origin,
one of which progressed to multiple lesions. Among the
others with repeat specimens, there were 13 with lesions
at the tubular origin which changed to multiple lesions.
Progression of lesions was accompanied by increases in
the index of chronic damage and proportion of globally
sclerosed glomeruli.
These findings are consistent with ideas that the ear-
liest segmental lesions in the nephrotic syndrome are at
the tubular origin, and that in some patients, these may
progress to multiple lesions, accompanied by develop-
ment of chronic damage in the kidney, and by a risk of
progression to ESRF. An implication is that multiple le-
sions are late in the course of segmental sclerosing dis-
orders. Not all patients with lesions at the tubular origin
showed progression, and some had a change to thin ad-
hesions. This supports the suggestion that lesions at the
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tubular origin are permanent, even though their appear-
ance may change [9, 10].
Patients with only one biopsy could not individually
confirm these changes with time, but as groups they gave
supporting evidence. The group with lesions at the tubular
origin had a significantly shorter duration of symptoms
than those with multiple lesions, consistent with an earlier
clinical stage, and also had a smaller index of chronic
damage and proportion of globally sclerosed glomeruli,
consistent with an earlier pathologic stage. They were
more likely to show a complete response, and many were
well at follow-up, using a strict definition of normal renal
function and normal protein excretion. Those who were
well had longer follow-up than the rest, and so their good
outcome was not due to a deceptively short length of
observation after the biopsy.
No patient with multiple lesions in the first or only
specimen had a complete response, and none was well at
follow-up. Patients with multiple lesions were more likely
to progress to ESRF, and this was sooner (Fig. 4), consis-
tent with a later clinical stage. The Cox analysis did not
show an independent effect on outcome of the pattern of
lesions, whether at the tubular origin or multiple, after ad-
justment for the amount of chronic renal damage, extent
of global sclerosis and number of segmental lesions, but
equally did not show that these other variables had an
independent effect. This was because all these features
were correlated with each other. For instance, patients
with lesions at the tubular origin had less chronic dam-
age than those with multiple lesions, but the extent of
chronic damage did not by itself explain the difference
in outcome. Because many patients with multiple lesions
had not had an earlier specimen, there is still a possibility
that multiple lesions are not always preceded by lesions at
the tubular origin, although the current paper shows that
lesions at the tubular origin come first in at least some
patients.
Multiple lesions only transformed to lesions at the
tubular origin in one circumstance, recurrence of the
nephrotic syndrome after transplantation. Altogether
there were 16 grafts, but two failed immediately and were
not at risk of recurrence. Of the other 14, 12 had recur-
rence. Nine showed lesions at the tubular origin, and two
progressed to multiple. This supports ideas that the ear-
liest lesions in the nephrotic syndrome are at the tubular
origin, and that multiple lesions develop later but are not
necessarily a different condition. The three transplants
with multiple lesions in the first biopsy after recurrence
may have been biopsied too late to detect the earliest
changes, but could also be evidence that multiple lesions
can develop without a stage of lesions only at the tubular
origin. Recurrence of FSGS in allografts is well known
[11], but there was no previous recognition that the first
lesions are usually at the tubular origin, nor that lesions
may change position.
Relation to other work on FSGS
A proposed classification is to divide FSGS, after ex-
clusion of segmental disorders developing in recogniz-
able conditions such as membranous nephropathy, into
five types: (1) FSGS, not otherwise specified (NOS); (2)
perihilar variant; (3) cellular variant; (4) tip variant; and
(5) collapsing variant [1]. Collapsing glomerulopathy has
such characteristic features that it can be considered a
distinct entity, “clinically, pathologically, and epidemio-
logically different from noncollapsing FSGS” [12], and is
uncommon in the United Kingdom (3/730 cases in the
later series). For these reasons, this condition was ex-
cluded from the current study.
Of the other types, the tip variant is equivalent to le-
sions at the tubular origin in the current paper, and FSGS
(NOS) corresponds with multiple lesions in the current
paper. The perihilar variant is common in conditions with
a reduced number of functioning nephrons [1], and these
rarely present with the nephrotic syndrome [5], which
was necessary for inclusion in the current study. The cel-
lular variant has had a change in definition. Originally,
this was “hypercellularity in the involved portion of the
glomerulus, increased cells in the surrounding Bowman’s
space, and reactive and proliferative changes in the asso-
ciated visceral epithelial cells” [13]. In the current study,
epithelial changes were common and had no relation to
outcome. A later definition of the cellular variant was “at
least one glomerulus with endocapillary hypercellularity
involving at least 25% of the tuft and causing occlusion
of the capillary lumen or lumina” [1]. This description
fit many specimens in the current study. The position of
lesions was not mentioned in the original definition, and
the later definition stressed that the tip variant must be
excluded. Possibly, if the consistent relation of the earliest
lesions to the tubular origin was not appreciated, these
may have been considered to show the cellular variant.
In the later series in the current paper, of 116 patients
with segmental lesions in their first or only specimen, 76
(66%) had lesions at the tubular origin. This is a strikingly
higher prevalence than reported from the United States,
where the tip variant was found in 2% and 17% of cases
with segmental lesions [abstracts; Lin J, et al, J Am Soc
Nephrol 13:452A, 2002; Franceschini N, et al, J Am Soc
Nephrol 14:285A, 2003]. This discrepancy is partly due
to the fact that the current paper was confined to cases
of the nephrotic syndrome, but may also reflect different
patterns of disease between the United Kingdom and the
United States, or different policies about renal biopsy,
particularly in the timing of biopsy after the onset of the
nephrotic syndrome.
Following the paper by Rich [14], FSGS is frequently
said to affect juxtamedullary glomeruli. In the current
paper, there were 14 nephrectomy and autopsy kidneys.
Segmental and/or global glomerular lesions were more
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marked in the inner cortex in six, and this supports the
view that the cortex may be affected asymmetrically, at
least in some stages. The other kidneys, with a more sym-
metrical distribution, may have been late, or may have
had a modified course because they were grafts, or, in the
nonprogressive case MRC3, may not have had the same
type of FSGS as the patients of Rich.
Focal means affecting only some glomeruli. A small
number of sections, as we studied particularly in the MRC
cases, underestimates how many glomeruli contain seg-
mental lesions. In serial section studies of some kidneys,
segmental lesions were reported in every or nearly every
glomerulus, meaning they were diffuse, not focal [9, 15,
16]. In others they were genuinely focal [17]. One rea-
son for this discrepancy may be that different variants
of FSGS were studied. Also, unless lesions at the tubu-
lar origin are specifically sought, they can be overlooked.
In the original MRC trial, a few cases called MCN were
found on review to have such lesions [3]. Thin adhesions
in particular are likely to be missed or their significance
neglected.
Relation to the glomerular tip lesion
The term glomerular tip lesion has been used with three
meanings. First, the original definition was the condition
in the nephrotic syndrome in which there were segmen-
tal lesions at the tubular origin in glomeruli that were
otherwise normal [9]. This was presumed to be MCN
with segmental abnormalities at the tubular origin [3, 8,
10]. Abnormalities at the tubular origin were common in
many disorders such as membranous nephropathy, were
not a disease in themselves, and were called tip changes
[18]. These were consequences of temporary prolapse of
acutely swollen glomerular tufts into the tubular open-
ing [19, 20]. Second, the term glomerular tip lesion was
used in another sense by others, who applied it to tip
changes in any condition, for instance diabetic glomeru-
lopathy [21]. Another example of this usage is description
of the glomerular tip lesion (in the sense of tip changes)
in MCN [22]. Finally, the third usage of glomerular tip
lesion corresponded with the tip variant of FSGS, and
was applied to specimens with tip changes in glomeruli
that could have mesangial hypercellularity [1, 23]. This
was excluded by the original definition. A group of pa-
tients was described who had tip changes in abnormal
glomeruli [5]. These were shown to have a risk of pro-
gression to more obvious segmental sclerosing lesions,
corresponding to multiple lesions in the current paper,
and to FSGS (NOS) in the proposed classification [1].
This group was considered to have an early stage of the
classical, nephrotic-associated FSGS [5].
One view is that the glomerular tip lesion in the third
sense, equivalent to the tip variant of FSGS, and to lesions
at the tubular origin in the current paper, is a distinct en-
tity, separate from both MCN and FSGS, but with clinical
features closer to those of MCN [23]. If this view is cor-
rect, the current paper shows that many patients have a
good outcome but that some will progress pathologically
and clinically. The overall prognosis is much better than
in those with FSGS (NOS).
Another interpretation is possible. This is that the
glomerular tip lesion in the third sense, the tip variant of
FSGS, and lesions at the tubular origin in the current pa-
per are not one condition, but at least two. The minimum
two conditions are MCN plus tip changes, corresponding
to the original definition of glomerular tip lesion [9], and
an early form of classical, nephrotic-associated FSGS [5].
The evidence that something closely related to MCN is
in this group is given by several observations, showing that
some patients behaved as though they had MCN. Half the
patients in the MRC series did not progress even though
they may not have been treated or had similar treatment
to some who progressed. Many patients in the later study
had a complete response of the nephrotic syndrome, and
many had normal renal function and no proteinuria at
prolonged follow-up. This included three who resolved
spontaneously, without immunosuppression. There were
seven patients with thin adhesions at the tubular origin
in their last or only biopsy, who had a long history of
relapsing, steroid-responsive nephrotic syndrome and a
complete response, and were well at follow-up.
Evidence for a condition with a poorer prognosis, re-
sembling the conventional view of nephrotic-associated
FSGS [24], is that half the patients in the MRC series
progressed, and so did several patients in the later series,
both relatively quickly. These developed multiple lesions
at medians of 1 year and 1.7 years after the first biopsy.
Some in both series progressed despite immunosuppres-
sion. The nephrotic syndrome recurred in five allografts
in three patients in the later group (Table 2).
If there were two conditions with lesions at the tubular
origin, differentiation between them was not easy. Part
of the problem was that the effect of immunosuppres-
sion on the natural course of these postulated conditions
was unknown. There was no single feature that allowed
clear distinction between those who had an excellent out-
come and those who did not, but three factors, namely,
large segmental lesions, mesangial increase, and exten-
sive acute tubular damage, collectively and individually,
were more common in those who did badly. These pa-
tients also had a higher proportion of glomeruli with seg-
mental lesions, but this was correlated with the presence
of large lesions, which were more likely to be seen on a
random section. These patients also had a higher index
of chronic damage, but the difference was too small to be
of practical use.
Whether the tip variant of FSGS [1] is one entity, as
others consider it [23], or more than one, as we consider
it [5], we have shown that its prognosis is better than that
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of FSGS (NOS), that at least some patients with FSGS
(NOS) had at an earlier stage shown the tip variant, and
that patients with FSGS (NOS) who have recurrence of
the nephrotic syndrome after renal transplantation may
show the tip variant in the graft.
Reprint requests to Alexander J. Howie, M.D., Department of
Histopathology, Royal Free Hospital, London NW3 2QG, United
Kingdom.
E-mail: a.j.howie@medsch.ucl.ac.uk
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